Oncology
Refine Search
Biotechnology
China's Kelun-Biotech has entered into a second collaboration and exclusive license agreement with Merck & Co. 27 July 2022
Pharmaceutical
US pharma major Bristol Myers Squibb’s (NYSE: BMY) dipped 2% to $73.63 pre-market today, as it released financial results for the second quarter of 2022, which it said reflect continued in-line product growth, strong momentum across the new product portfolio and continued pipeline progress. 27 July 2022
Pharmaceutical
The Johnson & Johnson subsidiary Janssen UK has named Maria Walsh its business unit director, oncology and hematology, cell and gene therapy and pulmonary hypertension. 27 July 2022
Pharmaceutical
Global contract development and manufacturing organization (CDMO) PCI Pharma Services (PCI) today announced a significant expansion of its world-class facility in Tredegar, Wales, UK, designed to help keep pace with the market growth of powerful, targeted oncology therapies. 27 July 2022
Biotechnology
Enhertu (trastuzumab deruxtecan) has been granted priority review in a new indication in the USA following results from the DESTINY-Breast04 Phase III trial showing that it is the first HER2-directed therapy to demonstrate a survival benefit in patients with HER2-low metastatic breast cancer. 26 July 2022
Biotechnology
Valo Therapeutics, a developer of immunotherapy platforms for cancer and infectious diseases, has announced the acquisition of an innovative tumor ‘fingerprint’ identification technology, called PeptiCHIP. 25 July 2022
Biotechnology
US discoverer of precision medicines for cancer and other diseases, Flare Therapeutics, today announced the appointment of Amit Rakhit as president and chief executive. 25 July 2022
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee, CHMP, has recommended that Rubraca (rucaparib camsylate) should no longer be used as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come back after at least two platinum-based chemotherapies and who cannot have further platinum-based therapy. 25 July 2022
Biotechnology
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. As the US Congress debates government action, we speak with EQRx chief executive Melanie Nallicheri about her company's market-based solution to high costs. 22 July 2022
Biotechnology
The European Medicines Agency’s human medicines committee (CHMP) recommended 10 novel medicines for approval at its July 2022 meeting. 22 July 2022
Biotechnology
British publicly-funded innovation catalyst The Cell and Gene Therapy Catapult (CGT Catapult) has launched a new consortium to support the development of personalized cell therapies. 22 July 2022
Biotechnology
Cancer Research UK and Sosei Heptares have agreed a deal to bring the Japanese drugmaker’s cancer immunotherapy drug candidate into a first-in-human trial. 21 July 2022
Pharmaceutical
Karyopharm Therapeutics’ shares were trading up 9% at $5.22 pre-market, as it announced that the European Commission (EC) has granted Marketing Authorization for Nexpovio (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor, in combination with once-weekly bortezomib (Velcade) and low-dose dexamethasone (SVd) for the treatment of adults with multiple myeloma who have received at least one prior therapy. 21 July 2022
Pharmaceutical
Swiss drugmaker Roche announced its financial results for the first half of 2022 on Thursday, as well as revealing that chief executive Severin Schwan will step down next March after 15 years in the top job. 21 July 2022
Biotechnology
Biotech company BigHat Biosciences raised a $75 million Series B round led by Section 32. 21 July 2022
Pharmaceutical
In a rare disappointment for leading PARP inhibitor Lynparza (olaparib), researchers are to stop the Phase III LYNK-003 trial after independent monitors judged it likely to fail. 20 July 2022
Biotechnology
Israeli-American company VBL Therapeutics was trading 79% lower in Wednesday’s pre-market activity. 20 July 2022
Biotechnology
Cell therapies are among the most researched treatment types for blood cancer and the product pipeline is oversaturated, with over 800 products currently in development for just five major blood cancers. 20 July 2022
Biotechnology
USA-based Tiziana Life Sciences has moved fast to strengthen its management team following this week’s announcement of the resignation of Kunwar Shailubhai as chief executive, chief scientific officer and board director, effective as of August 1. 19 July 2022
Pharmaceutical
US healthcare conglomerate Johnson & Johnson beat estimates for sales and earnings figures with its second quarter results. 19 July 2022
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze